PL3851537T3 - Leczenie hiperbilirubinemii - Google Patents

Leczenie hiperbilirubinemii

Info

Publication number
PL3851537T3
PL3851537T3 PL21151019.3T PL21151019T PL3851537T3 PL 3851537 T3 PL3851537 T3 PL 3851537T3 PL 21151019 T PL21151019 T PL 21151019T PL 3851537 T3 PL3851537 T3 PL 3851537T3
Authority
PL
Poland
Prior art keywords
hyperbilirubinemia
treatment
Prior art date
Application number
PL21151019.3T
Other languages
English (en)
Inventor
Federico Mingozzi
Giuseppe RONZITTI
Fanny COLLAUD
Andrés MURO
Giulia BORTOLUSSI
Original Assignee
Genethon
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, International Centre For Genetic Engineering And Biotechnology filed Critical Genethon
Publication of PL3851537T3 publication Critical patent/PL3851537T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/01017Glucuronosyltransferase (2.4.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21151019.3T 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii PL3851537T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305622 2014-04-25
EP14196400 2014-12-04

Publications (1)

Publication Number Publication Date
PL3851537T3 true PL3851537T3 (pl) 2024-09-16

Family

ID=53039406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21151019.3T PL3851537T3 (pl) 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii

Country Status (11)

Country Link
US (3) US10471132B2 (pl)
EP (4) EP4643946A3 (pl)
JP (3) JP6730193B2 (pl)
CN (2) CN114395559A (pl)
AU (1) AU2015250770B2 (pl)
CA (2) CA2942451C (pl)
DK (3) DK3851537T5 (pl)
ES (3) ES2971434T3 (pl)
FI (2) FI3546585T3 (pl)
PL (1) PL3851537T3 (pl)
WO (1) WO2015162302A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
MA43415A (fr) * 2015-12-09 2018-10-17 Modernatx Inc Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
JP7061067B2 (ja) * 2015-12-14 2022-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア クリグラー・ナジャー症候群の処置のための組成物
JP7007273B2 (ja) 2015-12-22 2022-01-24 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) 遺伝子治療用の改良された複合型二重組換えaavベクターシステム
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
CN105721252B (zh) * 2016-03-24 2020-09-25 腾讯科技(深圳)有限公司 数据包乱序度的测量方法和系统
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018046774A1 (en) 2016-09-12 2018-03-15 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
JP2020524996A (ja) 2017-06-16 2020-08-27 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
ES2986113T3 (es) * 2017-07-07 2024-11-08 Genethon Nuevos polinucleótidos que codifican una proteína FKRP humana
CA3077355A1 (en) * 2017-10-02 2019-04-11 American Gene Technologies International Inc. Vectors with promoter and enhancer combinations for treating phenylketonuria
CN111902539B (zh) 2018-02-07 2025-05-16 吉尼松公司 杂合调控元件
JP7142815B2 (ja) * 2018-06-21 2022-09-28 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN109082402B (zh) * 2018-08-06 2021-08-17 复旦大学 一种aav-dj型腺相关病毒体外高效感染类器官的用途
CN112654698A (zh) 2018-08-08 2021-04-13 吉尼松公司 用于治疗糖原贮积病iii的小型gde
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3864161A4 (en) * 2018-10-09 2022-11-23 The University of North Carolina at Chapel Hill Regulated gene editing system
CN113474459A (zh) * 2018-12-21 2021-10-01 吉尼松公司 用于基因疗法载体的表达盒
KR20210148101A (ko) 2019-02-04 2021-12-07 프리라인 테라퓨틱스 리미티드 폴리뉴클레오티드
JP7654562B2 (ja) * 2019-04-19 2025-04-01 ジェネトン 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
EP3980549A4 (en) * 2019-06-05 2023-07-26 Orchard Therapeutics (Europe) Limited COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOT CELLS
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
JP7719060B2 (ja) 2019-10-22 2025-08-05 ジェネトン キメラポリペプチド及びその使用
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
US20230313152A1 (en) 2020-08-24 2023-10-05 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022177597A1 (en) * 2021-02-16 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to enhance rna stability and translation and uses thereof
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001374A1 (en) * 1989-07-24 1991-02-07 Seragen, Inc. Prevention of internal initiation
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1997021824A2 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
ES2261489T3 (es) * 2000-10-13 2006-11-16 Chiron Corporation Fragmentos de intron a de citomegalovirus.
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
WO2006102643A2 (en) * 2005-03-24 2006-09-28 Caritas St. Elizabeth Medical Center Boston, Inc. Stably transformed bone marrow-derived cells and uses thereof
JP2008539698A (ja) * 2005-04-29 2008-11-20 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 転写後レベルでの核酸発現調節のための方法および組成物
WO2007120533A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
EP2164971B1 (en) 2007-06-15 2015-12-09 Mogam Biotechnology Research Institute Method for manufacturing active recombinant blood coagulation factor ix
EP2014301A1 (en) * 2007-07-13 2009-01-14 TopoTarget Germany AG Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CN101348786B (zh) * 2007-07-20 2011-05-11 谭孟群 一种人β珠蛋白基因及其重组腺相关病毒载体
AU2009297243B2 (en) * 2008-09-29 2015-10-29 Proyecto De Biomedicina Cima S.L. Porphobilinogen deaminase gene therapy
CN101671740B (zh) * 2009-10-19 2012-05-23 广州益善生物技术有限公司 Ugt1a1基因多态性检测的方法及液相芯片
CA2779689A1 (en) * 2009-11-06 2011-05-12 Enzymatics, Inc. Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase
ES2618899T3 (es) 2010-02-26 2017-06-22 The Children's Hospital Of Philadelphia Zimógeno de proteína C y procedimientos de utilización del mismo para prevenir las metástasis del cáncer
CA2853379C (en) * 2011-10-27 2020-11-24 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
CN102643906A (zh) * 2012-04-01 2012-08-22 周宏灏 焦磷酸测序法检测伊立替康个体化用药基因多态性的试剂盒及方法
CN104411338A (zh) * 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9458466B2 (en) * 2012-07-16 2016-10-04 Kyoto University Translational control system using RNA-protein interaction motif
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
CN103146804B (zh) * 2013-02-04 2015-04-22 中国科学院大连化学物理研究所 葡萄糖醛酸转移酶ugt1a1的特异性探针底物及应用
IL297919A (en) 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN104789532B (zh) * 2015-03-30 2019-06-11 汉恒生物科技(上海)有限公司 一种表达腺病毒的细胞株及高效制备腺病毒的方法

Also Published As

Publication number Publication date
CN106459932B (zh) 2022-01-11
JP7349931B2 (ja) 2023-09-25
EP3546585A1 (en) 2019-10-02
CN106459932A (zh) 2017-02-22
EP3546585B1 (en) 2025-09-10
ES2744565T3 (es) 2020-02-25
FI3851537T3 (fi) 2024-03-21
CA2942451A1 (en) 2015-10-29
ES2971434T3 (es) 2024-06-05
EP3851537B1 (en) 2023-12-27
US20170028036A1 (en) 2017-02-02
DK3851537T3 (da) 2024-03-18
CA3205555A1 (en) 2015-10-29
CA2942451C (en) 2024-09-10
US10471132B2 (en) 2019-11-12
DK3134530T3 (da) 2019-09-09
EP3851537A1 (en) 2021-07-21
JP2022088645A (ja) 2022-06-14
EP4643946A2 (en) 2025-11-05
EP3134530B1 (en) 2019-06-12
EP3134530A2 (en) 2017-03-01
AU2015250770B2 (en) 2020-10-01
WO2015162302A3 (en) 2015-12-30
EP4643946A3 (en) 2026-03-04
DK3546585T3 (da) 2025-11-03
ES3050307T3 (en) 2025-12-19
FI3546585T3 (fi) 2025-11-20
DK3851537T5 (da) 2024-08-19
CN114395559A (zh) 2022-04-26
US20190374619A1 (en) 2019-12-12
JP2017513501A (ja) 2017-06-01
WO2015162302A2 (en) 2015-10-29
JP6730193B2 (ja) 2020-07-29
AU2015250770A1 (en) 2016-09-29
JP2020103300A (ja) 2020-07-09
US20230414724A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
IL250677B (en) Cancer treatment using anti-nkg2a agents
PT3212233T (pt) Terapia combinada para o tratamento de doenças
PL3122358T3 (pl) Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
IL248856A0 (en) New treatment
IL246880A0 (en) Tumor treatment
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201410407D0 (en) Treatment of chagas disease
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417465D0 (en) Treatment of cancers
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201412285D0 (en) Therapeutic treatments
GB201412293D0 (en) Therapeutic treatments
GB201417719D0 (en) New treatment